StreetInsider.com News Articles

Tenaya Therapeutics, Inc. (TNYA) Reports In-Line Q4 EPS

Wed, 11 Mar 2026 16:46:55 -0400

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported Q4 EPS of ($0.12), in-line with the analyst estimate of ($0.12).

For earnings history and earnings-related data on Tenaya Therapeutics, Inc. (TNYA) click here.

Form 10-K Tenaya Therapeutics, For: Dec 31

Wed, 11 Mar 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260311/26146501.html

Form 10-K Tenaya Therapeutics, For: Dec 31

Wed, 11 Mar 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260311/26146501.html

Form 8-K Tenaya Therapeutics, For: Mar 11

Wed, 11 Mar 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260311/26146260.html

Form 8-K Tenaya Therapeutics, For: Mar 11

Wed, 11 Mar 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260311/26146260.html

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Wed, 11 Mar 2026 16:05:00 -0400

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026

New Research Supports TN-301’s Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model

Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals

December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027

SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Wed, 11 Mar 2026 16:05:00 -0400

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026

New Research Supports TN-301’s Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model

Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals

December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027

SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Wed, 11 Mar 2026 16:05:00 -0400

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026

New Research Supports TN-301’s Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model

Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals

December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027

SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Wed, 11 Mar 2026 16:05:00 -0400

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026

New Research Supports TN-301’s Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model

Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals

December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027

SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Wed, 11 Mar 2026 16:05:00 -0400

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026

New Research Supports TN-301’s Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model

Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals

December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027

SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Wed, 11 Mar 2026 16:05:00 -0400

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026

New Research Supports TN-301’s Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model

Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals

December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027

SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Wed, 11 Mar 2026 16:05:00 -0400

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026

New Research Supports TN-301’s Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model

Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals

December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027

SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Wed, 11 Mar 2026 16:05:00 -0400

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026

New Research Supports TN-301’s Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model

Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals

December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027

SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage

Tenaya presents preclinical data on TN-301 for muscle dystrophy treatment

Mon, 09 Mar 2026 08:30:51 -0400

Tenaya Therapeutics Inc. (NASDAQ: TNYA) presented preclinical data showing its HDAC6 inhibitor TN-301 outperformed the approved drug givinostat in treating Duchenne muscular dystrophy in laboratory studies. The data were presented at the Muscular Dystrophy Association's Clinical & Scientific Conference 2026.

In studies using mdx mice, TN-301 at doses as low as 3 mg/kg improved grip strength to normal levels within five weeks, while mice treated with givinostat at 10 mg/kg failed to reach normal performance levels. TN-301 treatment also reduced circulating creatine kinase activity, indicating reduced muscle cell injury.

In cardiomyocytes derived from human Duchenne muscular dystrophy stem cells, TN-301 corrected calcium

Tenaya presents preclinical data on TN-301 for muscle dystrophy treatment

Mon, 09 Mar 2026 08:30:51 -0400

In cardiomyocytes derived from human Duchenne muscular dystrophy stem cells, TN-301 corrected calcium

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

Mon, 09 Mar 2026 08:30:00 -0400

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy

New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions

Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development

ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

Mon, 09 Mar 2026 08:30:00 -0400

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy

New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions

Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

Mon, 09 Mar 2026 08:30:00 -0400

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy

New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions

Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

Mon, 09 Mar 2026 08:30:00 -0400

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy

New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions

Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development

Form 8-K Tenaya Therapeutics, For: Mar 04

Thu, 05 Mar 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260305/26115786.html

Form 8-K Tenaya Therapeutics, For: Mar 04

Thu, 05 Mar 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260305/26115786.html

Tenaya Therapeutics partners with Alnylam for heart disease targets

Thu, 05 Mar 2026 08:31:42 -0400

Tenaya Therapeutics Inc. (NASDAQ: TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (NASDAQ: ALNY) to discover genetic targets for cardiovascular disease treatments.

Under the agreement, Tenaya will validate up to 15 gene targets over a two-year period. The company will receive up to $10 million in upfront payments plus reimbursement for related costs. Alnylam will handle all development and commercialization activities for therapeutics associated with the identified targets.

Tenaya may receive up to $1.13 billion in development and commercial milestone payments if all genetic targets lead to approved cardiovascular disease therapeutics, according to the press release.

"By combining our modality agnostic target

Tenaya Therapeutics partners with Alnylam for heart disease targets

Thu, 05 Mar 2026 08:31:42 -0400

Tenaya Therapeutics Inc. (NASDAQ: TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (NASDAQ: ALNY) to discover genetic targets for cardiovascular disease treatments.

Tenaya may receive up to $1.13 billion in development and commercial milestone payments if all genetic targets lead to approved cardiovascular disease therapeutics, according to the press release.

"By combining our modality agnostic target

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

Thu, 05 Mar 2026 08:30:00 -0400

Agreement Combines Tenaya’s Expertise in Identification and Validation of
Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics

Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13 Billion

SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced a research collaboration agreement with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

Thu, 05 Mar 2026 08:30:00 -0400

Agreement Combines Tenaya’s Expertise in Identification and Validation of
Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics

Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13 Billion